DEC 05, 2017 6:00 AM PST

WEBINAR: Androgen signaling in advanced prostate cancer models using noninvasive hyper polarized MRI and mass spectrometry

Sponsored by: Agilent
Speaker

Abstract

DATE: December 5th, 2017
TIME:  6:00AM PT

Androgen receptor (AR) signaling remains a driver in the lethal phenotype of prostate cancer, castrate resistant prostate cancer (CRPC). Novel second generation enhanced androgen inhibitors, abiraterone acetate and enzalutamide, improve survival of CRPC patients following androgen deprivation therapy. However, a significant group of patients demonstrate primary resistance to these agents and other patients acquire resistance during therapy. The mechanisms of enhanced androgen inhibitor resistance are complex. AR-dependent mechanisms involve AR overexpression, AR mutation, intra-tumor ligand biosynthesis, modulation of co-activators and co-repressors and expression of AR spice variants. AR-independent tumors activate glucocorticoid receptor and differentiate to aggressive variant or neuroendocrine phenotype with loss of tumor suppressors.  Patient derived xenografts (PDX) developed from men with AR-positive or AR-negative CRPC were used to determine impact of AR signaling on glycolysis. We used two AR positive (MDA-PCa-133 and 180-30) and 2 AR negative (MDA-PCa-144 and 155) PDX grown in intact male mice. In vivo hyperpolarized MRI of each PDX was performed at a tumor volume of ~1.0 cm3 using 1-[13C]-pyruvate conversion to 1-[13C]-lactate. Ex vivo measurement of glycolytic metabolites, lactate, tricarboxylic acids and unique cancer metabolites were determined using NMR and mass spectrometry. We found increased glycolysis and alterations in other bioenergy metabolites in AR-positive PDX models and in low androgen environment (castration) versus AR-negative models. Our research supports the potential of hyperpolarized metabolic imaging in determining the underlying biology and in vivo phenotyping of CRPC.  

Learning Objectives:

  • the link between hyperpolarized imaging and quantitative mass spectrometry – proof of principle
  • metastatic prostate cancer being a diverse disease
  • analytical instrumentation in diagnostic and predictive marker development

 

For Research Use Only. Not for use in diagnostic procedures.

 


Show Resources
You May Also Like
FEB 15, 2023 7:00 AM PST
FEB 15, 2023 7:00 AM PST
Date: February 15, 2023 Time: 7:00am (PST), 10:00pm (EST), 4:00pm (CET) While not all microscopy samples can fluoresce, all can scatter light, and this scattered light can be imaged. This ha...
AUG 24, 2022 7:00 AM PDT
AUG 24, 2022 7:00 AM PDT
Date: August 24, 2022 Time: 7:00am (PDT), 10:00pm (EDT), 4:00pm (CEST) Light field microscopy was first introduced in 2006, and allows users to capture the 4D light field within the microsco...
NOV 16, 2022 7:00 PM PST
C.E. CREDITS
NOV 16, 2022 7:00 PM PST
Date: November 16, 2022 Time: 2:00pm (AEST) Date: November 17, 2022 7:00pm (PST), 10:00pm (EST), 4:00am (CET) The growth in FDA-approved cell and gene therapy products for the treatment of d...
OCT 13, 2022 9:00 AM +08
OCT 13, 2022 9:00 AM +08
First Broadcast: Date: October 12, 2022 Time: 8:00am PDT, 11:00am EDT Second Broadcast: Date: October 12, 2022 Time: 9:00am SGT The new Embedded CryoSPARC Live, now fully integrated with t...
SEP 13, 2022 8:00 AM PDT
SEP 13, 2022 8:00 AM PDT
Date: September 13, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Preparedness against pandemic diseases demands rapid-response vaccine technology and ready-to-use analytical methods...
AUG 10, 2022 10:00 AM PDT
AUG 10, 2022 10:00 AM PDT
Date: August 10, 2022 Time: 10:00am PDT, 1:00pm EDT The global pandemic has increased focus and scrutiny on molecular diagnostic assay development, resulting in a need for assays that provid...
DEC 05, 2017 6:00 AM PST

WEBINAR: Androgen signaling in advanced prostate cancer models using noninvasive hyper polarized MRI and mass spectrometry

Sponsored by: Agilent


Show Resources
Loading Comments...
Show Resources